EMA extends use advice for Regeneron COVID mix

Friday, 26. February 2021 12:28

The European Medicines Agency (EMA) announced on Friday that Regeneron's REGN-COV2, a mix of monoclonal antibodies casirivimab and imdevimab, can be used for treating COVID-19. The treatment is recommended for use in patients who don't need supplemental oxygen or who are at high risk of progressing to severe COVID-19.

The EU agency added that its recommendations can now be used to create national advice on the use of the antibody treatment.

The EMA is continuing a rolling review of REGN-COV2 and once it is finished it could be a basis for an EU marketing authorization.

Related Links: Regeneron Pharmaceuticals Inc.
Breaking the News / VP